Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995;39(Suppl 1):47S–50S. doi: 10.1111/j.1365-2125.1995.tb04503.x

An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive

P E Coates, R Mesure
PMCID: PMC1364937  PMID: 7547095

Abstract

1 The effects of tenidap sodium and placebo on the pharmacokinetics of a combined oral contraceptive (Microgynon 30®) were evaluated in 18 healthy premenopausal women in a double-blind, cross-over study lasting two menstrual cycles.

2 Tenidap (120 mg day-1) or placebo was given for 11 days, starting within 4 days of menstruation and Microgynon 30®, containing levonorgestrel (150 μg) and ethinyloestradiol (30 μg), was administered on day 10 of tenidap therapy.

3 The mean maximum plasma levonorgestrel concentrations (Cmax), time to Cmax (tmax) and area under the plasma time-concentration curves (AUC(0,t)) did not differ between subjects given tenidap or placebo. The Cmax, tmax and AUC(0,t) values for ethinyloestradiol did not differ between tenidap and placebo recipients. Only the ethinyloestradiol Cmax showed a significant difference (P = 0.02) between menstrual cycles 1 and 2 (252.9 pg ml-1 and 271.3 pg ml-1, respectively).

4 Co-administration of tenidap and Microgynon 30® was well tolerated and no subject withdrew from the study because of side-effects. There were no side-effects considered to be related to tenidap and no clinically significant laboratory abnormalities were considered to be related to treatment.

5 The results of the study suggest that the pharmacokinetics of the oestrogen and progestin components of the oral contraceptive Microgynon 30® are unlikely to be affected by concomitant administration of tenidap.

Keywords: tenidap sodium, oral contraceptive, levonorgestrel, ethinyloestradiol, pharmacokinetics

Full text

PDF
47S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dyas J., Turkes A., Read G. F., Riad-Fahmy D. A radioimmunoassay for ethinyl oestradiol in plasma incorporating an immunosorbent, pre-assay purification procedure. Ann Clin Biochem. 1981 Jan;18(Pt 1):37–41. doi: 10.1177/000456328101800108. [DOI] [PubMed] [Google Scholar]
  2. Gomaa A. A., Makarm M. H. Influence of aspirin on the pharmacokinetics of norethindrone. Contraception. 1987 Jun;35(6):611–618. doi: 10.1016/s0010-7824(87)80020-3. [DOI] [PubMed] [Google Scholar]
  3. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Macdonald J. I., Herman R. J., Verbeeck R. K. Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. Eur J Clin Pharmacol. 1990;38(2):175–179. doi: 10.1007/BF00265980. [DOI] [PubMed] [Google Scholar]
  6. Pettipher E. R. Pathogenesis and treatment of chronic arthritis. Sci Prog. 1989;73(292 Pt 4):521–534. [PubMed] [Google Scholar]
  7. Scavone J. M., Ochs H. R., Greenblatt D. J., Matlis R. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol. 1988;35(1):105–108. doi: 10.1007/BF00555518. [DOI] [PubMed] [Google Scholar]
  8. Sipe J. D., Bartle L. M., Loose L. D. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J Immunol. 1992 Jan 15;148(2):480–484. [PubMed] [Google Scholar]
  9. Smith G. M., Ward R. L., McGuigan L., Rajkovic I. A., Scott K. F. Measurement of human phospholipase A2 in arthritis plasma using a newly developed sandwich ELISA. Br J Rheumatol. 1992 Mar;31(3):175–178. doi: 10.1093/rheumatology/31.3.175. [DOI] [PubMed] [Google Scholar]
  10. Wilner K. D., Gardner M. J. Tenidap sodium does not alter the clearance or plasma protein binding of tolbutamide in healthy male volunteers. Br J Clin Pharmacol. 1995;39 (Suppl 1):39S–42S. doi: 10.1111/j.1365-2125.1995.tb04501.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. van Zwieten P. A. A survey of drug interaction. Int J Clin Pharmacol Biopharm. 1977 May;15(5):217–221. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES